Drawing on expertise at Durham and partner organisations across the biological, chemical and physical sciences we seek to synergize research foci to develop collaborative efforts for the identification and inhibition of novel antimicrobial targets, ultimately leading towards the development of novel therapies and preventative strategies.

By bridging the Departments of Chemistry and Bioscience, the Centre for Global Infectious Diseases (CGID) brings together specific, multidisciplinary expertise to tackle challenges in global infectious disease.

Examples of global impact delivered by members of CGID include a case study on the manufacture of anti-fungal agent Voriconazole (F2 Chemicals/Pfizer, $600m annual sales) for treatment of fungal infections; and work supporting a reduced cost preparation of the anti-fungal Flucytosine (Sanofi/MEPI) which is an important part of treatment for Cryptococcal Meningitis.

As well as developing impact, our members have worked together to secure multi-million pound funding via the RCUK GCRF Capacity and Capability Building scheme. This endeavour is focused on identifying viable target compounds for development into pharmaceutical tools against two insect-borne diseases (leishmaniasis and Chagas disease) which threaten the lives and health of millions in developing countries.

A further key strategic goal of CGID is to provide a focal point and established network to attract Early Career Research (ECR) Fellows to Durham and to provide mentorship to those already in post.